Zydus reports saroglitazar beat placebo in phase 2b MASH trial
In short
Zydus Therapeutics said its experimental drug saroglitazar did better than placebo in a phase 2b trial. After 52 weeks, 39.1% of patients on 4 mg and 32.4% on 2 mg had MASH resolution without worse fibrosis, versus 13.7% on placebo.
The result may help support the drug’s further development for adults with MASH and stage F2-F3 fibrosis.
What the reporting says
Zydus Therapeutics reported that saroglitazar achieved MASH resolution without worsening fibrosis in a phase 2b trial, with 39.1% of patients on the 4 mg dose and 32.4% on the 2 mg dose versus 13.7% on placebo. The study enrolled 189 adults with MASH and stage F2-F3 fibrosis and ran for 52 weeks. The results may support further development of the investigational drug.
Why it matters
Zydus Therapeutics reported phase 2b trial results for saroglitazar in 189 adults with MASH and stage F2-F3 fibrosis. The drug showed higher rates of steatohepatitis resolution without worsening fibrosis than placebo after 52 weeks, with 39.1% at 4 mg and 32.4% at 2 mg versus 13.7%. The figures are relevant to Zydus’s clinical development efforts and the broader MASH treatment pipeline.